Literature DB >> 3056855

Comparison of antibody avidity and titre elicited by peptide as a protein conjugate or as expressed in vaccinia.

A M Lew1, R F Anders, S J Edwards, C J Langford.   

Abstract

The immunogenicity of a malaria peptide presented in various forms was tested in terms of the quality and quantity of the antibody response in rabbits. Peptide conjugated to a protein carrier, diphtheria toxoid (DT), required strong adjuvants (e.g. muramyl dipeptide, MDP and Freund's adjuvant, FCA) to elicit high levels of antibody with high avidity. Alum was a poor adjuvant, producing the lowest titre and avidity of antibody compared with all the other groups. Peptide expressed in vaccinia (and without carrier) produced intermediate levels of antibody but the avidity of the antibodies produced were comparable to that produced by peptide conjugates given with muramyl dipeptide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056855      PMCID: PMC1384930     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  12 in total

Review 1.  The potential of synthetic peptides for vaccines.

Authors:  M W Steward; C R Howard
Journal:  Med Lab Sci       Date:  1985-10

2.  The importance of antibody affinity in the performance of immunoassays for antibody.

Authors:  M W Steward; A M Lew
Journal:  J Immunol Methods       Date:  1985-04-22       Impact factor: 2.303

3.  Expression of an enzymatically active parasite molecule in Escherichia coli: Schistosoma japonicum glutathione S-transferase.

Authors:  D B Smith; M R Rubira; R J Simpson; K M Davern; W U Tiu; P G Board; G F Mitchell
Journal:  Mol Biochem Parasitol       Date:  1988-01-15       Impact factor: 1.759

4.  Structure of the RESA gene of Plasmodium falciparum.

Authors:  J M Favaloro; R L Coppel; L M Corcoran; S J Foote; G V Brown; R F Anders; D J Kemp
Journal:  Nucleic Acids Res       Date:  1986-11-11       Impact factor: 16.971

5.  Antibody avidity determination by ELISA using thiocyanate elution.

Authors:  G R Pullen; M G Fitzgerald; C S Hosking
Journal:  J Immunol Methods       Date:  1986-01-22       Impact factor: 2.303

6.  Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

Authors:  G L Smith; M Mackett; B Moss
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

7.  Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity.

Authors:  C J Langford; S J Edwards; G L Smith; G F Mitchell; B Moss; D J Kemp; R F Anders
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

8.  Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection.

Authors:  I A Ramshaw; M E Andrew; S M Phillips; D B Boyle; B E Coupar
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

9.  Carrier-induced epitopic suppression, a major issue for future synthetic vaccines.

Authors:  M P Schutze; C Leclerc; M Jolivet; F Audibert; L Chedid
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

10.  Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein.

Authors:  M F Good; W L Maloy; M N Lunde; H Margalit; J L Cornette; G L Smith; B Moss; L H Miller; J A Berzofsky
Journal:  Science       Date:  1987-02-27       Impact factor: 47.728

View more
  11 in total

Review 1.  Where are we in the quest for vaccines for malaria?

Authors:  W A Siddiqui
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

Review 2.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

3.  Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195.

Authors:  G S Hui; L Q Tam; S P Chang; S E Case; C Hashiro; W A Siddiqui; T Shiba; S Kusumoto; S Kotani
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

4.  Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.

Authors:  S A Hammond; S J Cook; D L Lichtenstein; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

Review 5.  Vaccinia virus vectors: new strategies for producing recombinant vaccines.

Authors:  D E Hruby
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

6.  Immunogenicity of the Plasmodium falciparum glutamate-rich protein expressed by vaccinia virus.

Authors:  M Theisen; G Cox; B Høgh; S Jepsen; J Vuust
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Immunogenicity of the Plasmodium falciparum serine repeat antigen (p126) expressed by vaccinia virus.

Authors:  J A Tine; V Conseil; P Delplace; C De Taisne; D Camus; E Paoletti
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

Review 8.  Molecular adjuvants and immunomodulators: new approaches to immunization.

Authors:  A G Johnson
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

9.  Avidity progression of dietary antibodies in healthy and coeliac children.

Authors:  R Saalman; U I Dahlgren; S P Fällström; L A Hanson; S Ahlstedt; A E Wold
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

10.  Measuring antibody avidity to Plasmodium falciparum merozoite antigens using a multiplex immunoassay approach.

Authors:  Diane Wallace Taylor; Naveen Bobbili; Alex Kayatani; Samuel Tassi Yunga; Winifrida Kidima; Rose F G Leke
Journal:  Malar J       Date:  2020-05-01       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.